Frontispiece: Cell-Surface Engineering for Advanced Cell Therapy

Cyclosporine therapy for advanced Langerhans cell histiocytosis.

Prompted by evidence that Langerhans cell histiocytosis (LCH) is a nonmalignant disorder of immune regulation, we used cyclosporine (12 mg/kg/d orally) to treat three young children with advanced multisystem LCH. All three patients had partial responses to cyclosporine within 2 months of therapy, as evidenced by complete resolution of organ dysfunction and regression of the majority of lesions....

Systemic therapy for advanced renal cell carcinoma.

Renal cell carcinoma (RCC) accounts for approximately 3% of all cancers and is refractory to cytotoxic chemotherapy - immunotherapy has until recently been the standard of care for advanced disease. Randomised trials reported in the last 5 years have demonstrated that a number of agents including the monoclonal antibody, bevacizumab, and the kinase inhibitors - sorafenib sunitinib, temsirolimus...

Role of Stem Cells in Cardiac Cell Therapy and Tissue Engineering

Background: In spite of promising results of conventional treatments for myocardial infarction, including medications, stent implantation, and coronary artery bypass grafting, the disease and its complications, especially heart failure, are highly prevalent because these methods could not reverse the cell loss, which is the main problem. Currently, heart transplantation, as the last option f...

cell therapy for dermal reconstruction

Cell Therapy for Traumatic Brain Injury: Opportunities and Pitfalls

Today, stem cell transplantation is a hot topic in scientific circles as a novel therapeutic approach to repair the structure and function of central nervous system. The safe and neuroprotective effects of cell therapy in models and traumatic brain injury patients were evaluated in many experimental and clinical studies in recent decade and somewhat promising results were provided to the scient...